Our investors include OrbiMed, Creacion Ventures, Hankang Capital and Delos Capital, which are some of the world’s most renowned institutional investors who have a wealth of experience investing in the biopharmaceutical industry; while our leadership team, commanding a strong track record in translational medicine and drug development, comprises industry veterans who have previously served in senior positions at numerous world-leading multinational pharmaceutical companies, including Pfizer, AstraZeneca, Novartis, Arrowhead, Dicerna, and ONYX.